Eton Pharmaceuticals, Inc. (ETON)
NASDAQ • Healthcare
Last close at November 18, 2026 at 21:00 UTC
Metrics Over Time
Where the Money Goes
Q3 2026In plain terms: out of every $100 in revenue, Eton Pharmaceuticals, Inc. keeps $61 as net profit.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Revenue rose year over year for Eton Pharmaceuticals in the third fiscal quarter of 2026, based on preliminary results reported November 5, 2026, with revenue of about $57.9 million reflecting continued contributions from its marketed rare-disease medicines across endocrine, metabolic, and liver-related disorders. Cash generation was a key feature of the quarter, with operating cash flow of roughly $35.2 million. For the next period, consensus calls for EPS of $0.38 on revenue of $45.9 million.
About Eton Pharmaceuticals, Inc.
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) develops and commercializes rare-disease medicines as a specialty pharmaceutical company, with $80.0 million in FY2025 revenue. Its marketed portfolio spans endocrine, metabolic, and liver-related disorders, and includes products for severe primary IGF-1 deficiency, adrenal disorders, Wilson disease, phenylketonuria, homocystinuria, and tyrosinemia type 1.
Today's Snapshot
The day ended with ETON 2.6% lower at 61.99, in line with a weaker sector. Volume was about half of its usual level.
Trading Volume
Below 10d avg (870.9K)
471.9K
vs S&P 500 Today
Underperforming Market
-2.35%
Updated: November 18, 2026 at 21:14 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$39.48 - $61.37Buy
- RSI (14)57.80Neutral
- Stochastic %K (14, 3, 3)68.37Neutral
- MACD Level (12, 26)2.93Buy
Peers & Related Assets
Get premium market insights delivered directly to your inbox.